mesothelioma murine model [147]. Combination therapy also improved ORR in two patients with mesothelioma, who were resistant to gemcitabine or PD-1 inhibitor as monotherapy [147]. Likewise, evaluation of the safety and tolerability of the nivolumab as monotherapy or plus gemcitabine and cisplatin as...
adjacent to one another; and further optionally e) the molecule comprises two pairs of adjacent cationic amino acids and one or two pairs of adjacent lipophilic residues; for use in the treatment of a tumour by combined, sequential or separate administration with an immune checkpoint inhibitor. Th...
Response to immune checkpoint inhibitor (ICI) rechallenge in patients with metastatic renal cell carcinoma who progressed on prior ICI: A systematic review... 4547#Background:Several immune checkpoint inhibitor (ICI)-based combination regimens are standard-of-care for first-line treatment of metastatic...
which won the 2018 Nobel Prize in Physiology or Medicine, has revolutionized the treatment dilemma of various human malignancies [1,2,3,4]. The first immune checkpoint inhibitor approved by FDA named lpilimumab that targets cytotoxic T-lymphocyte-associated protein ...
Table 3. Clinical trials of immune checkpoint inhibitor in combination therapy for patients with sarcoma. Immune checkpoint inhibitorOther agentsNCT trial numberPhaseStatusParticipantsSarcoma subtype(s)Includes pediatric patients Immune checkpoint inhibitor in combination with another immunotherapy agent Atezolizuma...
Gunawan F, George E, Roberts A. Combination immune checkpoint inhibitor therapy nivolumab and ipilimumab associated with multiple endocrinopathies. Endocrinol Diabetes Metab Case Reports. 2018;2018:17-0146. ArticleGoogle Scholar Dillard T, Yedinak CG, Alumkal J, Fleseriu M. Anti-CTLA-4 antibody ...
It is now recognized that the combination of checkpoint inhibitors withchemoradiationcan enhance therapeutic effects. In addition, combinations of different checkpoint inhibitors appear to have added efficacy formalignanciessuch asmelanomacompared with an individual checkpoint inhibitor (i.e., ipilimumab with...
The composition of the intestinal microbiota regulates susceptibility to immune checkpoint inhibitor-induced colitis To understand how immune checkpoint perturbation impacts the colonic immune system, we administered anti-CTLA4/anti-PD-1 combination therapy to wild-type (WT) Balb/C mice. Combination checkp...
Immune checkpoint blockade (ICB) therapy for cancer has achieved great success both in clinical results and on the market. At the same time, success drives more attention from scientists to improve it. However, only a small portion of patients are responsive to this therapy, and it comes with...
The combination of avelumab and axitinib, a VEGF receptor inhibitor, has been evaluated in a phase IB treatment-naive patients with advanced renal cell carcinoma [78]. The doublet therapy demonstrated acceptable safety profile and early sign of clinical activity. The maximum tolerated dose establish...